Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile: Data Presented in Late-Breaker Poster at ADA 2012
Improved Glucose Control
PHILADELPHIA, June 9, 2012 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. HALO +3.58% today presented results from a Phase 4 study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. Interim data from this study indicate that pre-administration of Hylenex recombinant in the SAP provided a consistent ultrafast insulin action profile over the infusion set life that resulted in improved glucose control. A presenter will be available to discuss the poster on Sunday, June 10 from 12:00 - 2:00 PM EDT.
"Pre-administration of Hylenex at the time of infusion set change may provide more consistent insulin exposure and absorption, and improve control of postprandial hyperglycemia," said Marcus Hompesch, M.D., President and CEO, Profil Institute for Clinical Research, Chula Vista, CA. "Although preliminary, these data look encouraging and indicate that Hylenex could help people living with Type 1 diabetes reduce glucose fluctuations that are problematic and achieve tighter glucose control."